CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL
NCT00576225
Withdrawn
This study is designed to test whether CT-2103/carboplatin provides improved overall survival compared to paclitaxel/carboplatin in women with NSCLC who have estradiol levels \>30 pg/ml.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/14/2020
Locations: Scottsdale Medical Specialists, Scottsdale, Arizona +43 locations
Conditions: NSCLC
Register for Updates
Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC
NCT03256136
Completed
This research study is studying a drug intervention as a possible treatment for lung cancer. The drugs involved in this study are: * Nivolumab * Carboplatin * Pemetrexed * Ipilimumab
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/14/2020
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts +2 locations
Conditions: Lung Cancer
Register for Updates
A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer
NCT00723957
Completed
The purpose of this study is to determine whether progression-free survival with ixabepilone is superior to that achieved with paclitaxel plus carboplatin in participants with advanced nonsmall-cell lung cancer and beta III (βIII)-tubulin-positive tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/06/2020
Locations: Scripps Cancer Center, La Jolla, California +32 locations
Conditions: Advanced/Metastatic Non-Small Cell Lung Cancer
Register for Updates
A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
NCT01633970
Completed
This open-label, Phase Ib study that has six treatment arms is designed to assess the safety, pharmacology and preliminary efficacy of atezolizumab (MPDL3280A; an engineered anti-programmed death-ligand 1 \[PDL1\] antibody) administered with bevacizumab (Arm A) and with bevacizumab plus oxaliplatin, leucovorin, and 5-fluorouracil (5-FU) (FOLFOX) (Arm B), with carboplatin and paclitaxel (Arm C), with carboplatin and pemetrexed (Arm D), with carboplatin and nab-paclitaxel (Arm E), and with nab-pac... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/06/2020
Locations: University of Colorado Cancer Center, Aurora, Colorado +10 locations
Conditions: Cancer
Register for Updates
Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
NCT00054210
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of chemotherapy is more effective in treating stage IIIB, stage IV, or recurrent non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of polyglutamate paclitaxel plus carboplatin to that of paclitaxel plus carboplatin in treating patients who have s... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
10/02/2020
Locations: Hematology and Oncology Associates of Alabama, Birmingham, Alabama +34 locations
Conditions: Lung Cancer
Register for Updates
Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
NCT00551733
Terminated
RATIONALE: Drugs used in chemotherapy, such as carboplatin, paclitaxel, and paclitaxel poliglumex, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving carboplatin together with paclitaxel poliglumex is more effective than giving carboplatin together with paclitaxel in treating non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying carboplatin and paclitaxel poliglume... Read More
Gender:
FEMALE
Ages:
Between 18 years and 120 years
Trial Updated:
10/02/2020
Locations: Scottsdale Medical Specialists, Scottsdale, Arizona +40 locations
Conditions: Lung Cancer
Register for Updates
Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole
NCT02476955
Terminated
An Open-label Phase 1b Study of ARQ 092 in Combination with other Antineoplastic Agents in Subjects with Selected Solid Tumors
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/28/2020
Locations: Not set, Grand Rapids, Michigan +4 locations
Conditions: Solid Tumors, Ovarian Cancer, Endometrial Cancer
Register for Updates
PTX-200 and Carboplatin in Ovarian Cancer
NCT01690468
Terminated
The main purpose of this study is to determine if Triciribine (TCN) and carboplatin are safe and tolerable when given together, and to determine if this combination of drugs can help people with recurrent ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/22/2020
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Ovarian Cancer
Register for Updates
A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer
NCT01616303
Completed
This is a Phase 2 randomized study with two treatment arms to compare the effectiveness of oregovomab (a murine monoclonal antibody directed against cancer antigen 125 (CA125)) when combined with first-line chemotherapy (carboplatin and paclitaxel) to first-line chemotherapy (carboplatin and paclitaxel alone) in female patients with advanced ovarian cancer.
Gender:
FEMALE
Ages:
Between 18 years and 75 years
Trial Updated:
09/11/2020
Locations: University of Connecticut Health Center, Farmington, Connecticut +1 locations
Conditions: Ovarian Neoplasms
Register for Updates
BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab
NCT00625898
Terminated
The trial will determine the value of adding bevacizumab to chemotherapy plus trastuzumab in patients with resected node-positive or high risk node-negative, HER2-positive breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/09/2020
Locations: University of Alabama at Birmingham, Birmingham, Alabama +648 locations
Conditions: Breast Cancer
Register for Updates
Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.
NCT00367471
Completed
The purpose of this study is to determine the optimally-tolerated regimens (OTR) for lapatinib in combination with paclitaxel, carboplatin with and without trastuzumab in patients with metastatic breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/08/2020
Locations: Novartis Investigative Site, La Jolla, California +2 locations
Conditions: Neoplasms, Breast
Register for Updates
A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy
NCT01859741
Terminated
The study consists of a Phase1b lead-in portion to determine the maximum tolerated dose (MTD) of OMP-59R5 (tarextumab) in combination with etoposide (EP) for 6 cycles followed a Phase 2, multi center, randomized, placebo-controlled portion comparing the efficacy and safety of OMP-59R5 in combination with EP for 6 cycles followed by single agent OMP-59R5 relative to EP alone for 6 cycles in subjects receiving first-line therapy for extensive stage small cell lung cancer.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
09/07/2020
Locations: Highlands Oncology Group, Rogers, Arkansas +34 locations
Conditions: Stage IV Small Cell Lung Cancer
Register for Updates